common.study.topics.clinical

Testing Experimental Treatment for Lung Cancer

common.study.values.description

SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial

This multi-centre phase I dose-escalation study will use a time-to-event continual reassessment method (TIT-CRM). Accrual will start at level 1 (60 Gy in 8 fractions). Patients will be assigned to treatment doses using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3 toxicity of 30% or less.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Radiation - SBRT

Patients will be assigned to treatment doses using the TITE-CRM model.

participant.views.study.view.additional

participant.views.study.view.scientific-title

SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial

common.study.values.clinical-trial-id

NCT03306680

participant.views.study.view.id

yb8Vle